3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Withdrawn
1
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
140
Leukemia
97
Leukemia, Lymphocytic, Chronic, B-Cell
96
Precursor Cell Lymphoblastic Leukemia-Lymphoma
90
Hematologic Neoplasms
69
Myelodysplastic Syndromes
55
Lymphoma
47
Lymphoma, Non-Hodgkin
45
Lymphoma, B-Cell, Marginal Zone
34
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
34
Lymphoma, Mantle-Cell
33
Lymphoma, Follicular
33
Burkitt Lymphoma
32
Recurrence
28
Lymphoma, Large B-Cell, Diffuse
28
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
24
Hodgkin Disease
23
Neoplasms
22
Leukemia, Myelomonocytic, Chronic
22
Multiple Myeloma
21
Myeloproliferative Disorders
20
Waldenstrom Macroglobulinemia
19
Lymphoma, Large-Cell, Immunoblastic
19
Leukemia, Myeloid, Chronic-Phase
17
Congenital Abnormalities
16
Primary Myelofibrosis
15
Leukemia, Myeloid, Accelerated Phase
14
Leukemia, Biphenotypic, Acute
14
Mycosis Fungoides
13
Lymphoma, T-Cell, Cutaneous
13
Interventions
olorofim
1
Caspofungin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Invasive Pulmonary Aspergillosis
×
Other hematologic neoplasm
×
Clear all
NCT02856178
2018-02-15
SAFEGUARD
F2G Biotech GmbH
Phase 1/2
Withdrawn